Neurocrine Biosciences Inc
Incyte and Neurocrine Trade above 100-Day Moving Averages
On September 4, 2015, Incyte (INCY) closed trading at $115.88 and continued to trade above 20-day, 50-day, and 100-day moving averages. The stock outperformed the IBB.
Ultragenyx Woos Investors with Good Returns in Mid-Cap Space
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8
The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.
Anacor Underperformed the Top 10 Pharmaceutical Subgroup Stocks
Anacor Pharmaceuticals fell by 6.8% due to profit-booking. It had ~650,000 shares being traded. It closed at $107.17. It breached the 100-day moving average.
Biotech Stocks Hammered Badly Last Week after Clinton Comment
Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.
Neurocrine Biosciences Has Robust Late-Stage Pipeline
According to Neurocrine Biosciences’ first-quarter earnings investor presentation, the company expects to have a portfolio of three assets approved across four indications by the end of fiscal 2020.
Why Is Voyager Therapeutics Soaring Today?
Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX).
Why Neurocrine Biosciences Stock Rose 9.6% Yesterday
On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.
Why Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.
A Financial Overview of Supernus Pharmaceuticals in September
In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.
Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”
Why Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18
On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.
Versartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.
Ingrezza: Boosting Neurocrine’s Top Line
Neurocrine Biosciences’ primary focus is on neurological and endocrine-based diseases and disorders. Its leading product is Ingrezza.
How Is Teva Progressing with Its Specialty Assets Portfolio?
Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers.
Comparing Cara Therapeutics’ Financial Performance
Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]
Cara Therapeutics’ Collaboration Agreements
Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]
Analysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.
Elagolix May Advance the Treatment Paradigm in Women’s Health
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application for its investigational drug Elagolix had been granted priority review by the FDA.
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
Geographic Market Expansion to Boost Spinraza Sales in 2017
In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
Neurocrine Biosciences: Ingrezza, Collaborations, Ratings
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.
Uterine Fibroids Segment May Offer Opportunity for NBIX
According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix
While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).
Why Valbenazine Studies Seem Promising
In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.
Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.
Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids
Together, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) aim to develop Elagolix as a minimally invasive yet effective therapy for uterine fibroids
Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain
AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.
Elagolix May Become a Leading Uterine Fibroids Drug
In addition to endometriosis, AbbVie’s (ABBV) and Neurocrine Biosciences’s (NBIX) Elagolix is also being investigated as a therapy for uterine fibroids.
Elagolix May Become a Strong Growth Driver for AbbVie
On October 19, 2016, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced positive results from two phase 3 clinical trials at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo.
AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster
Due to significant unmet demand and limited competition in the women’s health segment, AbbVie expects Elagolix to become a blockbuster therapy.
Positive Top-Line Data May Help Secure FDA Approval for Valbenazine
Neurocrine Biosciences has seen positive results from Kinect 3, a phase-3 trial that tested the efficacy and safety of Valbenazine for tardive dyskinesia.
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.
Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?
If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
ICPT and XON Put Pressure on XBI’s Biotechnology Sector
Intrexon (XON) plummeted by 14.4% after it announced its 2Q15 results. As per the company’s press release, XON’s total revenue was $44.9 million.